Page last updated: 2024-10-28

hydroxychloroquine and Embryopathies

hydroxychloroquine has been researched along with Embryopathies in 4 studies

Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.

Research Excerpts

ExcerptRelevanceReference
"Hydroxychloroquine (HCQ), an orally administered Toll-like receptor antagonist widely used in lupus including during pregnancy, was evaluated for efficacy in reducing the historical 18% recurrence rate of CHB."5.34Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. ( Buyon, JP; Clancy, R; Cohen, RE; Copel, JA; Costedoat-Chalumeau, N; Cuneo, BF; Friedman, DM; Izmirly, P; Kim, M; Masson, M; Phoon, CKL; Robins, K; Saxena, A; Wainwright, BJ; Zahr, N, 2020)
"In the 1980's, pregnancies in systemic sclerosis (SSc) patients were considered to be at high risk for poor foetal and maternal outcome."2.44[Pregnancy in systemic sclerosis]. ( Bérezné, A; Mouthon, L, 2008)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's1 (25.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Izmirly, P1
Kim, M1
Friedman, DM1
Costedoat-Chalumeau, N1
Clancy, R1
Copel, JA1
Phoon, CKL1
Cuneo, BF1
Cohen, RE1
Robins, K1
Masson, M1
Wainwright, BJ1
Zahr, N1
Saxena, A1
Buyon, JP1
Gupta, R1
High, WA1
Butler, D1
Murase, JE1
Bérezné, A1
Mouthon, L1
Petri, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Preventive Approach to Congenital Heart Block With Hydroxychloroquine[NCT01379573]Phase 274 participants (Actual)Interventional2011-01-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Abnormal Fluid Collection

(NCT01379573)
Timeframe: At birth (approximately 9 months)

InterventionParticipants (Count of Participants)
Pregnant Women With Previous Child With Cardiac Neonatal Lupus0

Any Sign of Myocardial Injury, Without Change in Cardiac Rate or Rhythm

a) shortening fraction <28% = 2 SD below normal mean or qualitatively reduced systolic function; b) cardio-thoracic ratio >0.33; c) hydropic changes; d) moderate/severe tricuspid regurgitation. (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)

InterventionParticipants (Count of Participants)
Pregnant Women With Previous Child With Cardiac Neonatal Lupus0

Birth Weight <10% in the Context of Gestational Age

(NCT01379573)
Timeframe: At birth (approximately 9 months)

InterventionParticipants (Count of Participants)
Pregnant Women With Previous Child With Cardiac Neonatal Lupus1

Cutaneous Neonatal Lupus

(NCT01379573)
Timeframe: Up to 15 months (at birth - 9 months, and 6 months thereafter)

InterventionParticipants (Count of Participants)
Pregnant Women With Previous Child With Cardiac Neonatal Lupus4

Echocardiographic Densities Consistent With EFE Confirmed Postnatally

(see title) (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)

InterventionParticipants (Count of Participants)
Pregnant Women With Previous Child With Cardiac Neonatal Lupus0

Fetal Death Not Related to Cardiac Dysfunction

"An autopsy with full evaluation of the heart will be encouraged but cannot be mandated. If AV block or evidence of a cardiomyopathy can be proven, then these will provide the basis for final categorization. If not possible, the death will not be considered a recurrence rate but will be reported." (NCT01379573)
Timeframe: Up to 9 months

InterventionParticipants (Count of Participants)
Pregnant Women With Previous Child With Cardiac Neonatal Lupus0

Prematurity

(gestational age <37 weeks at birth) (NCT01379573)
Timeframe: At birth (approximately 9 months)

InterventionParticipants (Count of Participants)
Pregnant Women With Previous Child With Cardiac Neonatal Lupus9

Prolonged PR Interval (>150msec)

EKG at birth must confirm 1st degree AV block. It is also possible that a fetus developing 1st degree block on study medication might have developed more advanced block in the absence of study medication. (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)

InterventionParticipants (Count of Participants)
Pregnant Women With Previous Child With Cardiac Neonatal Lupus0

Recurrence of Advanced Heart Block

Echocardiogram reveals 2nd or 3rd degree AV block (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)

InterventionParticipants (Count of Participants)
Pregnant Women With Previous Child With Cardiac Neonatal Lupus5

Reviews

2 reviews available for hydroxychloroquine and Embryopathies

ArticleYear
[Pregnancy in systemic sclerosis].
    Presse medicale (Paris, France : 1983), 2008, Volume: 37, Issue:11

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antirheumatic Agents; Female; Fetal Diseases; Humans; Hydr

2008
Immunosuppressive drug use in pregnancy.
    Autoimmunity, 2003, Volume: 36, Issue:1

    Topics: Adrenal Cortex Hormones; Azathioprine; Breast Feeding; Cyclophosphamide; Cyclosporine; Female; Fetal

2003

Trials

1 trial available for hydroxychloroquine and Embryopathies

ArticleYear
Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers.
    Journal of the American College of Cardiology, 2020, 07-21, Volume: 76, Issue:3

    Topics: Administration, Oral; Adult; Autoantibodies; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fe

2020

Other Studies

1 other study available for hydroxychloroquine and Embryopathies

ArticleYear
Medicolegal aspects of prescribing dermatological medications in pregnancy.
    Seminars in cutaneous medicine and surgery, 2013, Volume: 32, Issue:4

    Topics: Acne Vulgaris; Alopecia; Dermatitis, Atopic; Dermatologic Agents; Dermatology; Female; Fetal Disease

2013